Enanta Pharmaceuticals Ownership | Who Owns Enanta Pharmaceuticals?


OverviewForecastRevenueFinancialsChart

Enanta Pharmaceuticals Ownership Summary


Enanta Pharmaceuticals is owned by 10.09% institutional investors, 6.57% insiders, and 83.34% retail investors. Farallon capital management is the largest institutional shareholder, holding 9.96% of ENTA shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.95% of its assets in Enanta Pharmaceuticals shares.

ENTA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockEnanta Pharmaceuticals10.09%6.57%83.34%
SectorHealthcare Stocks 279.18%10.62%-189.80%
IndustryBiotech Stocks 63.96%10.74%25.30%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Farallon capital management2.11M9.96%$12.12M
Blackrock funding, inc. /de2.04M9.64%$11.73M
Vanguard group1.98M9.38%$11.41M
Blackrock1.85M8.72%$23.96M
Morgan stanley1.46M6.88%$18.89M
Millennium management1.35M6.33%$7.44M
Krensavage asset management1.25M5.91%$16.23M
Marshall wace, llp930.09K4.40%$5.35M
Acadian asset management849.42K4.01%$4.88M
Northern trust845.12K3.99%$10.96M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Krensavage asset management1.25M7.45%$16.23M
Stonepine capital management590.74K3.17%$3.26M
Sio capital management177.00K0.29%$977.06K
Farallon capital management2.11M0.06%$12.12M
Sherbrooke park advisers33.45K0.06%$192.34K
Tang capital management126.66K0.05%$728.27K
Portland global advisors33.19K0.02%$190.81K
Pdt partners33.45K0.02%$192.33K
Quest partners22.26K0.02%$128.00K
Acadian asset management849.42K0.01%$4.88M

Top Buyers

HolderShares% AssetsChange
Millennium management1.35M0.00%449.94K
Stonepine capital management590.74K3.17%258.84K
Blackrock funding, inc. /de2.04M0.00%139.32K
Krensavage asset management1.25M7.45%126.75K
Dimensional fund advisors lp297.11K0.00%102.65K

Top Sellers

HolderShares% AssetsChange
Ra capital management---1.04M
Armistice capital---1.00M
Soleus capital management---785.55K
Morgan stanley1.46M0.00%-588.59K
Ameriprise financial70.43K0.00%-257.88K

New Positions

HolderShares% AssetsChangeValue
Thrivent financial for lutherans44.10K0.00%44.10K$254.00K
Norges bank40.70K-40.70K$234.03K
Sherbrooke park advisers33.45K0.06%33.45K$192.34K
Bank of montreal /can/31.75K0.00%31.75K$182.55K
Gsa capital partners llp30.73K0.01%30.73K$177.00K

Sold Out

HolderChange
Ifp advisors-3.00
Nelson, van denburg & campbell wealth management group-4.00
Innealta capital-16.00
Voisard asset management group-28.00
Gamma investing-29.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 20255-95.33%2,149,611-88.86%100.12%2-96.61%1-96.55%
Dec 31, 202432-71.17%5,786,937-72.69%270.27%17-69.09%9-71.88%
Sep 30, 202411111.00%21,189,162-3.74%1000.93%5627.27%32-27.27%
Jun 30, 2024100-6.54%22,011,926-1.25%1030.94%444.76%44-12.00%
Mar 31, 20241071.90%22,290,57011.98%1051.18%42-22.22%5016.28%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF629.60K2.95%-
Vanguard Total Stock Mkt Idx Inv629.60K2.95%-
iShares Russell 2000 ETF515.73K2.41%252.00
Vanguard Strategic Small-Cap Equity Inv338.10K1.58%37.34K
Vanguard Institutional Extnd Mkt Idx Tr294.95K1.38%-
Columbia Small Cap Value I A271.73K1.28%3.30K
Vanguard VIF Small Co Gr206.07K0.97%-47.29K
Columbia Small Cap Value I200.68K0.95%200.68K
Fidelity Small Cap Index200.20K0.94%-
Vanguard Strategic Equity Inv180.74K0.85%-

Recent Insider Transactions


DateNameRoleActivityValue
Feb 12, 2025Luly Jay R. President and CEOBuy$256.05K
Dec 06, 2024Kieffer Tara Lynn Chief Product Strategy OfficerSell$18.40K
Dec 06, 2024Luu Brendan Chief Business OfficerSell$18.40K
Dec 06, 2024Rottinghaus Scott T. Chief Medical OfficerSell$6.98K
Dec 06, 2024Or Yat Sun Chief Scientific OfficerSell$20.88K

Insider Transactions Trends


DateBuySell
2025 Q11-
2024 Q4-6
2024 Q3-3
2024 Q2-1
2024 Q1--

ENTA Ownership FAQ


Who Owns Enanta Pharmaceuticals?

Enanta Pharmaceuticals shareholders are primarily institutional investors at 10.09%, followed by 6.57% insiders and 83.34% retail investors. The average institutional ownership in Enanta Pharmaceuticals's industry, Biotech Stocks , is 63.96%, which Enanta Pharmaceuticals falls below.

Who owns the most shares of Enanta Pharmaceuticals?

Enanta Pharmaceuticals’s largest shareholders are Farallon capital management (2.11M shares, 9.96%), Blackrock funding, inc. /de (2.04M shares, 9.64%), and Vanguard group (1.98M shares, 9.38%). Together, they hold 28.98% of Enanta Pharmaceuticals’s total shares outstanding.

Does Blackrock own Enanta Pharmaceuticals?

Yes, BlackRock owns 8.72% of Enanta Pharmaceuticals, totaling 1.85M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 23.96M$. In the last quarter, BlackRock increased its holdings by 8.46K shares, a 0.46% change.

Who is Enanta Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Krensavage asset management is Enanta Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 7.45% of its assets in 1.25M Enanta Pharmaceuticals shares, valued at 16.23M$.

Who is the top mutual fund holder of Enanta Pharmaceuticals shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Enanta Pharmaceuticals shares, with 2.95% of its total shares outstanding invested in 629.6K Enanta Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools